Nicholas Saraceno, Editor

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

The company’s twice-daily, branded ruxolitinib cream 1.5% presents a significant reduction in abscess and inflammatory nodule (AN) count for the treatment of Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa.

A USC study discovers that an increasing share of both generic and brand-name meds are being excluded from approval.

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

The CDMO’s multi-million-dollar expansion project features commercial manufacturing suites and peptide manufacturing plants.

The CDC urges healthcare providers to preserve their current supply.

The pTau217 antibody helps pinpoint pathological changes related to the disease.

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

The purchase boosts the parties’ sterile liquid manufacturing capabilities.

A JAMA Network Open study dives into how the utilization of a digital patient portal changed during the COVID-19 pandemic, while also exploring ways that multimorbidity and socioeconomic disparities affected those statistics.

The offering reportedly helps avoid product quarantine.

A cohort study investigates a potential correlation between the stresses caused by Mother Nature and mental health.

IPX203—an oral formulation carbidopa/levodopa extended-release capsules —would expand Zambon’s neurology portfolio.

Rob Besse offers a breakdown of the third-party logistics (3PL) process, including lessons that these providers have learned coming out of the pandemic.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

An MDVIP study reports that 61% of people feel hassled by the current structure.

An investigation evaluates whether SNAP benefits can also influence hypertension patients’ lack of medication adherence.

Current production of Qdenga will increase to 50 million doses a year.

A cohort study explores the association of Medicare Advantage enrollment with post-acute care use, along with patient outcomes among retired state employees.

The company’s cloud technology services aim to assist healthcare and pharma with AI integration.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

The CRO’s FortreaRx doubles in size, including a boost in cold chain storage, while also continuing to improve its patient access services.

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

A cohort study investigates how a change in clinical guidelines, an expanded label, and reduction in drug prices can impact the use of PCSK9 inhibitors as a treatment for atherosclerotic cardiovascular disease.

OneScan 7.1 is expected to boost compliance, while also improving pharma supply chain efficiencies.

A trial set out to determine whether empagliflozin can help prevent hospitalizations and extend life for patients with heart failure, while not hurting the US payers’ pockets.

Phase III results from Keytruda (pembrolizumab)’s NRG-GY018 trial help influence the agency’s decision.

Arshad M. Khanani, MD, MA, FASRS, will help lead development efforts for sozinibercept, a potential wet AMD treatment.